In the case of PC, the high expression level of HHLA2 not only reveals the occurrence, development, metastasis, prognosis and immune escape mechanism, but may also suggest that HHLA2 can be used as a potential target for immunotherapy of PC patients [27, 28]. This evidence concerns the gene HHLA2 and pachyonychia congenita.